↓ Skip to main content

The annual rate of coronary artery calcification with combination therapy with a PCSK9 inhibitor and a statin is lower than that with statin monotherapy

Overview of attention for article published in npj Aging, June 2018
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • Among the highest-scoring outputs from this source (#26 of 162)
  • High Attention Score compared to outputs of the same age (91st percentile)

Mentioned by

twitter
49 X users
video
1 YouTube creator

Citations

dimensions_citation
35 Dimensions

Readers on

mendeley
29 Mendeley
Title
The annual rate of coronary artery calcification with combination therapy with a PCSK9 inhibitor and a statin is lower than that with statin monotherapy
Published in
npj Aging, June 2018
DOI 10.1038/s41514-018-0026-2
Pubmed ID
Authors

Yuichi Ikegami, Ikuo Inoue, Kaiji Inoue, Yuichi Shinoda, Shinichiro Iida, Seiichi Goto, Takanari Nakano, Akira Shimada, Mistuhiko Noda

Abstract

Statins and/or PCSK9 inhibitors cause the regression of coronary atheroma and reduce clinical events. However, it currently remains unclear whether these drugs modulate coronary atheroma calcification in vivo. Coronary artery calcium (CAC) scores (Agatston Units, AUs) were estimated in 120 patients receiving coronary computed tomographic angiography (CCTA) (63% males; median age 56 years). The CAC scores were compared among the three groups: (1) neither statin nor PCSK9 inhibitor therapy, (2) statin monotherapy, and (3) statin and PCSK9 inhibitor combination therapy in an unpaired cross-sectional study. Additionally, CCTA was performed twice at an interval in 15 patients undergoing statin monotherapy to compare the previous (baseline) and subsequent (follow-up) CAC scores in a paired longitudinal study. In addition, a PCSK9 inhibitor was administered to 16 patients undergoing statin therapy. Before and after that, CCTA was performed twice to compare the previous and subsequent CAC scores in a paired longitudinal study. The unpaired cross-sectional study and paired longitudinal study consist of completely different patients. Among 120 patients, 40 (33%) had a CAC score >100 AUs. The median CAC score increased in the following order: statin group, statin and PCSK9 group, and no-statin-no-PCSK9 group. Annual CAC score progression was 29.7% by statin monotherapy and 14.3% following the addition of the PCSK9 inhibitor to statin therapy. The annual rate of CAC with the combination therapy with a PCSK9 inhibitor and a statin is lower than that with statin monotherapy. CAC may be prevented with PCSK9 Inhibitor.

X Demographics

X Demographics

The data shown below were collected from the profiles of 49 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 29 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 29 100%

Demographic breakdown

Readers by professional status Count As %
Researcher 6 21%
Other 4 14%
Student > Master 4 14%
Student > Ph. D. Student 3 10%
Student > Bachelor 2 7%
Other 3 10%
Unknown 7 24%
Readers by discipline Count As %
Medicine and Dentistry 10 34%
Engineering 4 14%
Biochemistry, Genetics and Molecular Biology 3 10%
Computer Science 2 7%
Immunology and Microbiology 1 3%
Other 2 7%
Unknown 7 24%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 29. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 25 August 2023.
All research outputs
#1,341,613
of 25,401,381 outputs
Outputs from npj Aging
#26
of 162 outputs
Outputs of similar age
#28,336
of 342,324 outputs
Outputs of similar age from npj Aging
#2
of 2 outputs
Altmetric has tracked 25,401,381 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 94th percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 162 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 37.9. This one has done well, scoring higher than 84% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 342,324 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 91% of its contemporaries.
We're also able to compare this research output to 2 others from the same source and published within six weeks on either side of this one.